Effect of JTV-506, a novel vasodilator, on experimental angina model in rats

Journal of Cardiovascular Pharmacology

Volumn 31, Issue 2, 1998, Pages 322-326

  Hirata, Yukiya ^a   Miyai, Hisato ^a   Mabuchi, Yukiyo ^a   Aisaka, Kazuo ^a  

^a JAPAN TOBACCO INC   (Japan)

Author keywords

Angina model; JTV 506; Potassium channel opener; Vasodilator

Indexed keywords

4 [(1,6 DIHYDRO 1 METHYL 6 OXO 3 PYRIDAZINYL)AMINO] 3 HYDROXY 2,2 BIS(METHOXYMETHYL)CHROMAN 6 CARBONITRILE; ANTIANGINA PECTORIS AGENT; ARGIPRESSIN; LEMAKALIM; METHACHOLINE; NICORANDIL; NIFEDIPINE; POTASSIUM CHANNEL; POTASSIUM CHANNEL STIMULATING AGENT; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ANGINA PECTORIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; HEART RATE; INTRADUODENAL DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANGINA PECTORIS; ANIMALS; ARGININE VASOPRESSIN; BLOOD PRESSURE; CHROMANS; CROMAKALIM; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; HEART RATE; INJECTIONS, INTRAVENOUS; MALE; METHACHOLINE CHLORIDE; MOLECULAR STRUCTURE; NIACINAMIDE; NICORANDIL; NIFEDIPINE; RATS; RATS, SPRAGUE-DAWLEY; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 0031911270     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199802000-00020     Document Type: Article

References (24)

1. + channels in cardiovascular medicine. Paris: Springer-Verlag France, 1993: 293-303.
2. Cho H, Kato S, Sayama S, et al. Synthesis and selective coronary vasodilatory activity of 3,4-dihydro-2,2-bis(methoxymethyl)-2H-1-benzopyran-3-ol derivatives: novel potassium channel openers. J Med Chem 1996;39:3797-805.
3. + channels. Trends Pharmacol Sci 1989;10:431-5.
4. Longman SD, Hamilton TC. Potassium channel activator drugs: mechanism of action, pharmacological properties, and therapeutic potential. Med Res Rev 1992;12:73-148.
5. Edwards G, Weston AH. The pharmacology of ATP-sensitive potassium channels. Annu Rev Pharmacol Toxicol 1993;33:597-637.
6. Buckingham RE, Clapham JC, Hamilton TC, Longman SD, Norton J, Poyser RH. BRL-34915, a novel antihypertensive agent: comparison of effects on blood pressure and other hemodynamic parameters with those of nifedipine in animal models. J Cardiovasc Pharmacol 1986;8:798-804.
7. Longman SD, Clapham JC, Wilson C, Hamilton TC. Cromakalim, a potassium channel activator: a comparison of its cardiovascular haemodynamic profile and tissue specificity with those of pinacidil and nicorandil. J Cardiovasc Pharmacol 1988;12:535-42.
8. Hof RP, Quast U, Cook NS, Blarer S. Mechanism of action and systemic and regional hemodynamics of the potassium channel activator BRL34915 and its enantiomers. Circ Res 1988;62:679-86.
9. Clapham JC, Hamilton TC, Longman SD, Buckingham RE, Campbell CA, Ilsley GL. Antihypertensive and haemodynamic properties of potassium channel activating (-)enantiomer of cromakalim in animal models. Arzneimittelforschung 1991;41:385-91.
10. Hirata Y, Miyai H, Kanada A, Aisaka K. Effect of JTV-506, a novel vasodilator, on coronary vessels in vitro and in vivo. Cardiac and vascular effects of JTV-506, a coronary artery-selective potassium channel opener, in experimental animals. J Mol Cell Cardiol 1996; 28:A309.
11. Hirata Y, Aisaka K. Effect of JTV-506, a novel vasodilator, on coronary blood flow in conscious dogs. J Cardiovasc Pharmacol 1997;29:397-405.
12. Sakai K. Akima M, Aono J. Evaluation of drug effects in a new experimental model of angina pectoris in the intact anesthetized rat. J Pharmacol Methods 1981;5:325-36.
13. Uchida W, Shibasaki K, Asano M, Takenaka T. Antianginal effects of YM-16154-4 in various experimental angina models. J Cardiovasc Pharmacol 1993;21:701-8.
14. Suzuki Y, Miyai H, Hirata Y, Aisaka K. Cardiac effect of JTV-506, a new coronary artery-selective potassium channel opener, in anesthetized and conscious dogs. Jpn J Pharmacol 1996;71 (suppl I): 135.
15. Yasue H, Omote S, Takizawa A, Nagao, A. Coronary arterial spasm in ischemic heart disease and its pathogenesis. Circ Res 1983;52 (suppl I):147-52.
16. Stephen FV, Thomas HH. Effects of calcium-channel antagonist on large and small coronary arteries in conscious dogs. Circulation 1982;3:579-88.
17. Clapham JC, Hamilton TC, Longma SD, et al. Anti-hypertensive and hemodynamic properties of potassium channel activating (-)enantiomer of cromakalim in animal models. Arzneimittelforschung 1991; 41:385-91.
18. Jean-Francosis G, Christophe DR, Alain B. Effects of cromakalim and pinacidil on large epicardial and small coronary arteries in conscious dogs. J Pharmacol Exp Ther 1990;255:836-42.
19. Matury FM, Sharon EM, Maret M, et al. Coronary vasoconstriction induced by vasopressin. Circulation 1991;83:2111-21.
20. Lamping KG, Kanatuka H, Eastham CL, Chilian WM, Marcus ML. Nonuniform vasomotor responses of the coronary microcirculation to serotonin and vasopressin. Circ Res 1989;65:343-51.
21. Karasawa A, Kubo K, Shuto K, Oka T, Nakamizo N. Antianginal effects of the new calcium antagonist benidipine hydrochloride in anesthetized rats and spontaneously hypertensive rats: electrocardiographic study. Arzneimittelforschung 1988;38:1702-7.
22. Grover GJ, Dzwonczyk S, Parham CS, Sleph PG. The protective effects of cromakalim and pinacidil on reperfusion function and infarct size in isolated perfused rat hearts and anesthetized dogs. Cardiovasc Drugs Ther 1990;4:465-74.
23. + channel opener aprikalini (RP 52891) reduces experimental infarct size in dogs in the absence of hemodynamic changes. J Pharmacol Exp Ther 1991;259:961-7.
24. Cole WC, McPherson CD, Sontag D. ATP-Regulated channels protect the myocardium against ischemia/reperfusion damage. Circ Res 1991;69:571-81.